UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)

Japanese journal of clinical oncology, 2021-03, Vol.51 (3), p.498-503

2021

Volltextzugriff (PDF)

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer

Cancer science, 2022-05, Vol.113 (5), p.1808-1820

2022

Volltextzugriff (PDF)

SY14-3 Immunotherapeutic strategies for each breast cancer subtype

Annals of oncology, 2022-07, Vol.33, p.S438

Hara, Fumikata

2022

Volltextzugriff (PDF)

EL16 Breast cancer (Perioperative medical treatment)

Annals of oncology, 2022-07, Vol.33, p.S457

Hara, Fumikata

2022

Volltextzugriff (PDF)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

Scientific reports, 2022-03, Vol.12 (1), p.4813-4813, Article 4813

2022

Volltextzugriff (PDF)

NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy

Breast cancer research and treatment, 2020-07, Vol.182 (2), p.325-332

2020

Volltextzugriff (PDF)

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

The lancet oncology, 2016, Vol.17 (1), p.90-98

2016

Volltextzugriff (PDF)

SY16-3 De-escalation in medical oncology

Annals of oncology, 2021-07, Vol.32, p.S260-S260

Hara, Fumikata

2021

Volltextzugriff (PDF)

Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer

BMC cancer, 2024-09, Vol.24 (1), p.1156-7, Article 1156

2024

Volltextzugriff (PDF)

Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study

Biological and Pharmaceutical Bulletin, 2024/02/10, Vol.47(2), pp.411-416

2024

Volltextzugriff (PDF)

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study

Breast cancer (Tokyo, Japan), 2021-07, Vol.28 (4), p.896-903

2021

Volltextzugriff (PDF)

Survey on adverse events associated with drug therapy for breast cancer patients

BMC women's health, 2024-10, Vol.24 (1), p.545-10, Article 545

2024

Volltextzugriff (PDF)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

International journal of clinical oncology, 2019-03, Vol.24 (3), p.262-273

2019

Volltextzugriff (PDF)

Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy

Supportive care in cancer, 2021, Vol.29 (1), p.437-443

2021

Volltextzugriff (PDF)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

BMC cancer, 2022-01, Vol.22 (1), p.36-36, Article 36

2022

Volltextzugriff (PDF)

Current standard and future perspectives in the post-operative treatment of triple negative breast cancer

Annals of oncology, 2018-10, Vol.29, p.vii38-vii38

Hara, Fumikata

2018

Volltextzugriff (PDF)

SY27-4Current standard and future perspectives in the post-operative treatment of triple negative breast cancer

Annals of oncology, 2018-10, Vol.29 (suppl_7)

Hara, Fumikata

2018

Volltextzugriff (PDF)

Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives

Breast cancer (Tokyo, Japan), 2023-09, Vol.30 (5), p.820-830

2023

Volltextzugriff (PDF)

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Breast (Edinburgh), 2021-02, Vol.55, p.63-68

2021

Volltextzugriff (PDF)

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer

Cancer science, 2016-10, Vol.107 (10), p.1465-1470

2016

Volltextzugriff (PDF)

Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial

Frontiers in oncology, 2023-07, Vol.13, p.1216813-1216813

2023

Volltextzugriff (PDF)

Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer

Acta medica Okayama, 2021-06, Vol.75 (3), p.357-362

2021

Volltextzugriff (PDF)

Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial)

Japanese journal of clinical oncology, 2018-04, Vol.48 (4), p.388-391

2018

Volltextzugriff (PDF)

Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Breast cancer (Tokyo, Japan), 2022-01, Vol.29 (1), p.131-143

2022

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(112)
Berichte
(2)

Sprache

Englisch
(109)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(16)
Breast Cancer
(15)
Japanese Journal Of Clinical Oncology
(12)
Cancer Research
(11)
Annals Of Oncology
(10)
Breast Cancer Research And Treatment
(6)
Acta Medica Okayama
(4)
Cancer Letters
(4)
Gan To Kagaku Ryoho
(4)
Bmc Cancer
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer

SY14-3 Immunotherapeutic strategies for each breast cancer subtype

EL16 Breast cancer (Perioperative medical treatment)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

SY16-3 De-escalation in medical oncology

Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer

Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study

Survey on adverse events associated with drug therapy for breast cancer patients

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

Current standard and future perspectives in the post-operative treatment of triple negative breast cancer

SY27-4Current standard and future perspectives in the post-operative treatment of triple negative breast cancer

Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer

Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial

Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer

Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial)

Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Suchergebnisse filtern